ABN Amro Rothschild to float second Merlin biotech

Merlin Biosciences is pushing ahead with the float of a second biotech investment despite its first exit two months ago now standing nearly 20% below the issue price.

Merlin has hired ABN Amro Rothschild to float Microscience, a UK developer of vaccines which include a promising product to prevent travellers' diarrhoea.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump